Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $28.9552W HIGH $49.32
Volume
749.14 K
Value Traded
18.38 M
Short % Float
10.84%
-0.25%Week
+2.72%1 Month
-14.79%3 Month
+18.84%6 Month
-34.47%5 Year
-96.9%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.05 B
EPS (TTM)
0.47
P/E Ratio
84.67
Ent. Value
1.82 B
Total Shares
51.20 M
Float Shares
50.60 M
Insiders
1.19%
Institutions
108.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VCEL Catalyst Timeline
Dated clinical, regulatory and corporate events for Vericel Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vericel Corporation
521Total events
5Upcoming
102Tier-1 (high impact)
2013 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Quarterly UpdateCorporate
Vericel reports Q2 2026 financial results with total revenue of $77.5 million
●EU MAA SubmissionMACIApprovedEx-US Regulatory
MACI marketing authorization application submitted to UK MHRA
cartilage defects of the kneesource ↗
▲Quarterly UpdateMACIApprovedCorporate
MACI Q2 2026 revenue growth of 23% to $65.5 million
cartilage defects of the kneesource ↗
▲Quarterly UpdateNexoBridApprovedCorporate
NexoBrid Q2 2026 revenue growth of 33% year-over-year
eschar removal in thermal burnssource ↗
◆Oral PresentationPresentation
Vericel to present at 2026 Truist Securities MedTech Conference
▲FDA ApprovalMACIApprovedFDA Decision
FDA approval for MACI commercial manufacturing at new Burlington facility
cartilage defects of the kneesource ↗
▲Partnership / LicenseNexoBridApprovedCorporate
BARDA award valued at up to $197 million for procurement and advanced development of NexoBrid
eschar removal in thermal burnssource ↗
▲Timing GuidancePresentation
Full-year 2026 revenue guidance raised by $10 million to $326-$336 million
▲Product LaunchMACIApprovedPost-Market
Start of commercial production of MACI at new facility
repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adultssource ↗
▲Partnership / LicenseNexoBridApprovedCorporate
BARDA contract award for procurement and advanced development of NexoBrid
severe thermal burns and blast trauma injuriessource ↗
▲FDA ApprovalMACIApprovedFDA Decision
FDA approval for MACI commercial manufacturing at Burlington facility
repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adultssource ↗
●Trial InitiationTrial
Initiation of clinical study for MACI Ankle expected in second half of 2025
cartilage defects of the anklesource ↗
◆Trial InitiationMACIApprovedTrial
MACI Ankle program clinical study initiation expected in Q4 2025
cartilage defects of the anklesource ↗
▲Enrollment MilestoneMACIApprovedTrial
More than 800 MACI Arthro surgeons trained to date
cartilage defects of the kneesource ↗
▲Quarterly UpdateMACIApprovedCorporate
MACI net revenue $55.7M in Q3 2025, 25% growth YoY
cartilage defects of the kneesource ↗
●Quarterly UpdateNexoBridApprovedCorporate
NexoBrid net revenue $1.5M in Q3 2025
thermal burnssource ↗
▲Quarterly UpdateCorporate
More than 800 MACI Arthro surgeons trained to date
cartilage defects (arthroscopic delivery)source ↗
▲IND ClearanceMACIApprovedIND
FDA IND clearance for Phase 3 MACI Ankle clinical study
cartilage defects of the anklesource ↗
▲IND ClearanceIND
FDA IND clearance for Phase 3 MACI Ankle clinical study
cartilage defects in the anklesource ↗
◆Trial InitiationMACIApprovedTrial
On track to initiate MACI Ankle clinical study in second half of 2025
cartilage defects of the anklesource ↗
◆Trial InitiationTrial
Expect to initiate clinical study for MACI Ankle in second half of 2025
cartilage defects of the anklesource ↗
●IND SubmissionIND
IND submission for MACI Ankle expected in first half of 2025
cartilage defects of the anklesource ↗
◆Oral PresentationPresentation
Vericel to present at Bank of America Securities 2025 Healthcare Conference
▲Quarterly UpdateCorporate
Second quarter total revenue and MACI revenue growth expected to be in low- to mid-20% range
◆Trial InitiationMACIApprovedTrial
MACI Ankle IND submission expected in H1 2025 and clinical study initiation in H2 2025
cartilage defects of the anklesource ↗
●IND SubmissionMACIApprovedIND
MACI Ankle IND submission expected in H1 2025
cartilage defects of the anklesource ↗
◆Oral PresentationPresentation
Vericel to present at 43rd Annual J.P. Morgan Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How VCEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-06-29 | NexoBrid (anacaulase / concentrate of proteolytic enzymes enriched in bromelain) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$0M
Pipeline Value
$1.3B
Commercial Value
Overvalued
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 58%
Small Cap(rank 382 of 658)
Percentile Rank
Vericel Corporation faces pipeline headwinds (34/100), with 1 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $306.3M x 4.3 = $1.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| MACI | $262M | $213M | +23% |
| Epicel | $40M | - | - |
| NexoBrid | $5M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MACI Monoclonal antibodyNCT06915233 | Chondral Defect | Phase 3 | RECRUITING | 354 | Jul 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every VCEL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NexoBrid | deep thermal burns | Phase 3 | 2023-09-28 | More than 93% of the patients treated with NexoBrid achieved complete eschar removal following one application of NexoBrid compared with 4% in the GV arm (P<0.0001); Surgical excision was lower in the NexoBrid arm when compared to the SOC group (4% vs. 72%; P<0.001); The estimated median time to complete eschar removal was 1.02 and 3.83 days for the NexoBrid and SOC treatment arms, respectively (P<0.0001)Read More | Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBridRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN FDirector | Option | 7,000 7,000 held | $0.00 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VCEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 2.2 % (120 %) | 64.92 M | 1.46 M | 90.99% ( 695.15 K) |
VCEL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VCEL ranks across every disease it competes in
Competitive Position is a premium feature
See how VCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVCEL News
VCELVericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
Vericel Corporation announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference scheduled for September 15, 2026. The presentation will highlight the company's advanced therapies in sports medicine and severe burn care. A webcast of the event will be accessible via their Investor Relations website.
Read more →VCELVericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
Vericel Corporation reported a strong second quarter for 2026, with total revenue rising 22% to $77.5 million, driven by significant growth in MACI and Burn Care products. The company raised its full-year revenue guidance to between $330 million and $340 million and announced a $200 million share repurchase program. Net income for the quarter was $2.2 million, reflecting a positive trend in financial performance.
Read more →VCELVericel to Report Second Quarter 2026 Financial Results on July 30, 2026
Vericel Corporation announced it will report its second quarter 2026 financial results on July 30, 2026. A conference call and webcast will be held at 8:30 a.m. ET to discuss the results and business highlights. The live webcast will be accessible on the company's Investor Relations website, with a replay available for one year.
Read more →VCELVericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Vericel Corporation announced its participation in the 2026 Truist Securities MedTech Conference scheduled for June 16, 2026. The presentation will highlight the company's advanced therapies for sports medicine and severe burn care. A webcast will be available on Vericel's Investor Relations website for those interested in the presentation.
Read more →VCELVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Vericel Corporation announced strong financial results for the first quarter of 2026, with total revenue increasing by 30% to $68.4 million. Key areas of growth included MACI revenue, which grew by 22%, and Burn Care revenue, which surged by 91%. The company also reported a significant increase in adjusted EBITDA, up 195% to $9.6 million. Notably, Vericel has raised its full-year revenue guidance by $10 million, reflecting confidence in sustained growth. Despite a reported net loss, the firm holds substantial cash reserves and remains on track for future profit and operational targets.
Read more →VCELVericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Vericel Corporation will announce its first-quarter 2026 financial results on May 7, 2026. A conference call and webcast will be held at 8:30 a.m. ET to discuss these results and business highlights. The live webcast will be accessible via the company's Investor Relations website, with a replay available for one year.
Read more →VCELVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
Vericel Corporation has secured a ten-year contract worth up to $197 million from BARDA for the procurement and development of NexoBrid. The contract includes initial funding for establishing a Vendor Managed Inventory system and developing a next-generation formulation. This partnership aims to enhance U.S. preparedness for mass casualty events involving severe burns and blast trauma injuries.
Read more →VCELVericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
Vericel Corporation has received FDA approval for its new advanced therapy manufacturing facility in Burlington, Massachusetts. This approval allows for the commercial production of MACI, a cartilage repair product, starting in Q2 2026. The facility will significantly increase manufacturing capacity and supports potential commercialization of MACI outside the United States.
Read more →VCELVericel to Present at Multiple Upcoming Investor Conferences
Vericel Corporation has announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Healthcare Conference and the Leerink Partners 2026 Global Healthcare Conference. The presentations will highlight the company's advanced therapies for sports medicine and severe burn care. Webcasts of the events will be available on Vericel's Investor Relations website.
Read more →VCELVericel Reports Fourth Quarter and Full-Year 2025 Financial Results
Vericel Corporation reported strong financial results for Q4 and full-year 2025, with total revenue of $276.3 million and a 21% growth in MACI revenue. The company achieved a record gross margin of 79% in Q4 and a net income increase of 59%. CEO Nick Colangelo expressed optimism for continued growth in 2026, despite rising operating expenses.
Read more →VCELVericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
Vericel Corporation will announce its fourth-quarter and full-year 2025 financial results on February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and business highlights. Investors can access the live webcast and presentation slides on the company's website.
Read more →VCELVericel Announces Preliminary 2025 Financial Results and Business Updates
Vericel Corporation announced preliminary financial results for 2025, projecting total revenue of $276 million, with MACI revenue expected at $239.5 million. The company reported a 23% growth in both total revenue and MACI revenue for the fourth quarter. CEO Nick Colangelo expressed optimism for continued growth and profitability in 2026, highlighting the company's momentum.
Read more →VCEL▲ +6.1%on this news
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Vericel Corporation has announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2026, at 2:15 p.m. ET. The presentation will be accessible via a webcast on the company's Investor Relations website. Vericel is noted for its innovative therapies in sports medicine and severe burn care, marketing three products in the U.S. market. This event represents an opportunity for Vericel to showcase its advancements and connect with the investment community.
Read more →VCELVericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
Vericel Corporation announced its participation in the Stephens Annual Investment Conference on November 20, 2025. The company will engage in a fireside chat at 11:00 a.m. ET, which will be accessible via a webcast. Vericel is recognized for its advanced therapies in sports medicine and severe burn care.
Read more →VCELVericel Reports Third Quarter 2025 Financial Results
Vericel Corporation reported strong financial results for Q3 2025, achieving a record total revenue of $67.5 million, driven by a 25% increase in MACI revenue. The company also reported a net income of $5.1 million, a turnaround from a loss in the previous year. Operating cash flow reached $22.1 million, indicating robust financial health. However, rising operating expenses and uncertainties regarding future growth remain concerns.
Read more →About Vericel Corporation
Headquarters25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
BIOPHARMAWATCH ELITE PLUS
Trade the next VCEL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime